ArticleScientific reports2025
Prevalence and risk factors for major arterial bleeding in fragility pelvic fractures in the aging population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fragility pelvic fractures (FPF) are increasingly common among elderly patients and, despite being caused by low-energy mechanisms, can result in major arterial bleeding (MAB). However, few studies have examined the prevalence and predictors of MAB in this population. This study aimed to evaluate prevalence and potential risk factors associated with MAB in elderly patients with FPF. This retrospective cohort study used data from the Japan Trauma Data Bank. The study included patients (age ≧ 65 years) with FPF between 2010 and 2021, defining FPF as pelvic fractures caused by a ground-level fall. Demographic, comorbidities, and antithrombotic use were analyzed. MAB was operationally defined by the performance of therapeutic angioembolization (TAE). Multivariable logistic regression was performed to identify predictors of MAB and in-hospital mortality. A total of 1,354 patients met inclusion criteria; 80 patients (5.9%) underwent TAE. Compared with the non-MAB group, the MAB group had significantly higher rates of liver disease, cerebral vascular disease, use of antithrombotic agents, systolic blood pressure (SBP) < 90 mmHg, and lower Glasgow Coma Scale scores. A multivariable logistic regression analysis revealed that age (OR 1.04, 95% CI 1.01-1.07), male sex (OR 2.42, 95% CI 1.49-3.93), cerebral vascular disease (OR 2.11, 95% CI 1.21-3.67), liver disease (OR 6.23, 95% CI 2.36-16.40), and SBP < 90 mmHg (OR 5.43, 95% CI 2.96-9.97) were independently associated with MAB. MAB itself was independently associated with higher in-hospital mortality (OR 4.3, 95% CI 2.1-8.9). Notably, 28% of in-hospital deaths occurred within 48 h and 50% within 7 days of admission. Despite their low-energy origin, FPFs can lead to life-threatening hemorrhage requiring invasive hemostatic intervention. A subset of elderly patients-particularly those with comorbidities or hypotension upon admission-are at elevated risk of MAB and poor outcomes. Early recognition and targeted intervention strategies are essential to improve survival in this growing and vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.